Requires non-invasive prenatal testing for pregnant persons and health insurance coverage for non-invasive prenatal testing.
Impact
If enacted, the bill will require that healthcare providers inform pregnant individuals about the risks associated with chromosomal abnormalities and the benefits of undergoing non-invasive testing. Each person will need to acknowledge they have received this information before the test is conducted. This change in procedure aims to enhance the screening process and ensure that individuals are aware of their options and potential outcomes regarding prenatal care.
Summary
Assembly Bill 2013 seeks to mandate non-invasive prenatal testing for all pregnant individuals in New Jersey. The legislation requires hospitals, birthing centers, and healthcare practitioners to offer a blood test that screens for chromosomal abnormalities, including Down syndrome, to every pregnant person starting at ten weeks of pregnancy. The bill emphasizes the importance of adhering to the industry best practices and guidelines as set forth by recognized medical bodies such as the American College of Obstetricians and Gynecologists.
Contention
While the bill promotes health and supports early detection of potential issues during pregnancy, there may be concerns regarding the potential implications for parental choice. Opponents might argue that mandating testing could lead to unnecessary anxiety or pressure on expectant mothers to act upon positive test results. Additionally, the regulation requires that all relevant health insurers cover the costs of these tests, which could lead to debates over coverage mandates and health insurance practices within New Jersey.
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Requires licensed health care professionals providing prenatal care to offer and screen, upon request, pregnant patients with history of depression for postpartum depression.